Andriy Moshyk

Andriy Moshyk

Bristol-Myers Squibb Co. - New York / United States
Economics & Econometrics / Economics
AD Scientific Index ID: 4391168
-
person_outline Andriy Moshyk's MOST POPULAR ARTICLES
1-) Five-year survival with combined nivolumab and ipilimumab in advanced melanomaJ Larkin, V Chiarion-Sileni, R Gonzalez, JJ Grob, P Rutkowski, CD Lao, ...New England Journal of Medicine 381 (16), 1535-1546, 201919902019
2-) Integrating feedback from a clinical data warehouse into practice organisationA Grant, A Moshyk, H Diab, P Caron, F de Lorenzi, G Bisson, L Menard, ...International journal of medical informatics 75 (3-4), 232-239, 2006652006
3-) Depression and mortality in the visually‐impaired, community‐dwelling, elderly population of QuebecM Tournier, Y Moride, T Ducruet, A Moshyk, S RochonActa ophthalmologica 86 (2), 196-201, 2008442008
4-) Cost-effectiveness of daclatasvir plus sofosbuvir-based regimen for treatment of hepatitis C virus genotype 3 infection in CanadaA Moshyk, MJ Martel, AA Tahami Monfared, R GoereeJournal of medical economics 19 (2), 191-202, 2016302016
5-) Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067MM Regan, CM Mantia, L Werner, AA Tarhini, J Larkin, FS Hodi, ...Journal for immunotherapy of cancer 9 (11), 2021292021